Abstract  Description  Claims  Drawing  Search report  Cited references 

US63007477   [0001] 
CN1345054   [0002] 
CN74566   [0002] 
US7598257B   [0014] 
WO2016035014A1   [0014] 
US8722693B   [0014] 

Remington: The Science and Practice of Pharmacy   [0023] 
Remington's Pharmaceutical Sciences   [0023] 
Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia   [0084] 
A Novel Coronavirus from Patients with Pneumonia in China, 2019   [0084] 
Covid-19: WHO declares pandemic because of ''alarming levels'' of spread, severity, and inaction   [0084] 
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China   [0084] 
Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths   [0084] 
Clinical Characteristics of Coronavirus Disease 2019 in China   [0084] 
Clinical outcome of 55 asymptomatic cases at the time of hospital admission infected with SARS-Coronavirus-2 in Shenzhen, China   [0084] 
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China   [0084] 
Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan: A Retrospective Observational Study   [0084] 
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study   [0084] 
Imaging and Clinical Features of Patients With 2019 Novel Coronavirus SARS-CoV-2: A systematic review and meta-analysis   [0084] 
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19   [0084] 
Race to find COVID-19 treatments accelerates   [0084] 
Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome   [0084] 
Persistence of lung inflammation and lung cytokines with high-resolution CT abnormalities during recovery from SARS   [0084] 
Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome   [0084] 
Analysis of serum cytokines in patients with severe acute respiratory syndrome   [0084] 
The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality   [0084] 
Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology   [0084] 
Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study   [0084] 
COVID-19: combining antiviral and anti-inflammatory treatments   [0084] 
Multiple organ infection and the pathogenesis of SARS   [0084] 
Ruxolitinib   [0084] 
Ruxolitinib treatment for SR-aGVHD in patients with EBV-HLH undergoing allo-HSCT   [0084] 
FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease   [0084] 
Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial   [0084] 
Ruxolitinib for the treatment of lymphoma-associated hemophagocytic lymphohistiocytosis: A cautionary tale   [0084] 
China National Health Commission   [0084] 
COVID-19 pneumonia: CT imaging evolution characteristics of thoracic lesions in recovery stage   [0084] 
Coronavirus disease (COVID-2019) R&D   [0084] 
Pathological findings of COVID-19 associated with acute respiratory distress syndrome   [0084] 
A pathological report of three COVID-19 cases by minimally invasive autopsies   [0084] 
The Immunology of Macrophage Activation Syndrome   [0084] 
Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome   [0084] 
Management of cytokine release syndrome related to CAR-T cell therapy   [0084] 
Chemokines and Chemokine Receptors in Lymphoid Tissue Dynamics   [0084] 
IL-12p40: an inherently agonistic cytokine   [0084] 
Macrophage inflammatory protein-1   [0084] 
VEGF receptor signalling - in control of vascular function   [0084] 
Clinical diagnosis and classification criteria: Diagnosis and treatment scheme of 2019-nCoV pneumonia   [0114] 
Guidelines for Biosafety Protection of 2019-nCoV pneumonia   [0158] 
Technical Guidelines for Laboratory Testing of 2019-nCoV pneumonia   [0158] 
Lancet   [0162] 
Lancet.   [0162] 
Blood   [0162] 
Blood   [0162] 
Nat Rev Clin Oncol.   [0162] 
Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome   [0162] 
MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile   [0162] 
Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians   [0162] 
Primary myelofibrosis: Older age and high JAK2V617F allele burden are associated with elevated plasma high-sensitivity C-reactive protein levels and a phenotype of progressive disease   [0162] 
Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study   [0162] 
The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms   [0162] 
Therapeutic activity of multiple common gamma-chain cytokine inhibition in acute and chronic GVHD   [0162] 
Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis   [0162] 
Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis   [0162] 
Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: First case report   [0162] 
Ruxolitinib for refractory/relapsed hemophagocytic lymphohistiocytosis   [0162]